Concepedia

Stephanie Noviello

SN

Statistics

Publications

48

Citations

6.1K

H-Index

28

Active since

2002

Affiliations

Bristol-Myers Squibb (United States)(Current)

Johns Hopkins University

Johns Hopkins Medicine

Clinical Research Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

Stephanie Noviello is an author at Bristol-Myers Squibb (United States) specializing in viral hepatitis, antiviral therapy, and infectious diseases.

ORCID

Publications per year

2002–2023

48

Publications

48

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman et al. · New England Journal of Medicine · 2009 · 1.2K citations · Full text

, , +14

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

Alexander Thompson, Andrew J. Muir, Mark S. Sulkowski et al. · Gastroenterology · 2010 · 723 citations · Full text

, , +17

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet · 2018 · 532 citations

, , +14

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

Stefan Zeuzem, Peter Ferenci, Jan Šperl et al. · Journal of Hepatology · 2005 · 463 citations · Full text

, , +16

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Fred Poordad, Eugene R. Schiff, John M. Vierling et al. · Hepatology · 2016 · 459 citations · Full text

, , +17

1–5 of 48